About Auron Therapeutics
Auron Therapeutics is a company based in Wellesley (United States) founded in 2018 by Kate Yen, Matt Vander Heiden, Eytan Stein, and Ross Levine. Auron Therapeutics has raised $103.84 million across 4 funding rounds from investors including Lilly, Genedit and Creyon Bio. Auron Therapeutics offers products and services including AURIGIN and AUTX-703. Auron Therapeutics operates in a competitive market with competitors including Syndax, Annexon, Adicet Bio, ImmunoACT and Orca Bio, among others.
- Headquarter Wellesley, United States
- Founders Kate Yen, Matt Vander Heiden, Eytan Stein, Ross Levine
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$103.84 M (USD)
in 4 rounds
-
Latest Funding Round
$27 M (USD), Series B
Feb 04, 2025
-
Investors
Lilly
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Auron Therapeutics
Auron Therapeutics offers a comprehensive portfolio of products and services, including AURIGIN and AUTX-703.
AI-driven tool for identifying cell state-specific targets in drug discovery
Targets KAT2A/B for treating cancers like SCLC and AML
People of Auron Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Auron Therapeutics
Auron Therapeutics has successfully raised a total of $103.84M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $27 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Auron Therapeutics
Auron Therapeutics has secured backing from 13 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Lilly, Genedit and Creyon Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments in healthcare and biotech are made.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Auron Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Auron Therapeutics
Investment portfolio details for Auron Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Auron Therapeutics
Detailed financials for Auron Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Auron Therapeutics Comparisons
Peer comparison for Auron Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Auron Therapeutics
Auron Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Syndax, Annexon, Adicet Bio, ImmunoACT and Orca Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
Detailed competitors of Auron Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Auron Therapeutics
Complete news archive for Auron Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Auron Therapeutics
Auron Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Auron Therapeutics is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Kate Yen is the current CEO of Auron Therapeutics. They have also founded this company.
Auron Therapeutics is a funded company, having raised a total of $103.84M across 4 funding rounds to date.
Auron Therapeutics was established in 2018 in Wellesley, United States, within the biotechnology sector focused on oncology. Proprietary differentiation therapy is developed for hematologic malignancies, where endogenous cellular programs are reactivated to induce tumor cell maturation and shift cancer tissue toward a normal phenotype. This approach targets conditions such as acute promyelocytic leukemia by converting malignant promyelocytes into non-cancerous neutrophils.
Auron Therapeutics offers AURIGIN and AUTX-703.
Auron Therapeutics has 13 investors. Key investors include Lilly, Genedit, Creyon Bio, Mubadala, and Totus Medicines.